From: Role of mast cells in the pathogenesis of severe lung damage in COVID-19 patients
Parameter | COVID-19 group (n = 30) | Control group (n = 9) | p-value |
---|---|---|---|
Tryptase-positive MCs | |||
Non-Degranulated MCs | 3.59 (2.36; 7.35) | 2.00 (1.78; 2.44) | 0.005 |
Degranulated MCs | 22.46 (17.47; 36.89) | 19.78 (15.78; 26.22) | 0.309 |
Single MCs | 23.34 (18.12; 37.78) | 18.22 (16.89; 22.00) | 0.167 |
Collaborative Diligence | 1.97 (1.33; 3.28) | 1.33 (0.89; 1.78) | 0.029 |
Total | 35.78 (24.0; 50.22) | 28.00 (24.00; 35.11) | 0.505 |
Chymase-positive MCs | |||
Non-Degranulated MCs | 0.22 (0.00; 0.67) | 1.11 (0.89; 1.11) | 0.004 |
Degranulated MCs | 9.07 (3.56; 13.33) | 4.44 (2.00; 5.33) | 0.039 |
Single MCs | 7.95 (3.78; 12.74) | 4.44 (3.11; 5.56) | 0.161 |
Collaborative diligence | 0.89 (0.00; 1.78) | 0.00 (0.00; 0.44) | 0.009 |
Total | 15.53 (6.67; 25.87) | 5.56 (3.56; 6.44) | 0.014 |